Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | XBP1 | P17861 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610987 | 0.74 | — | — | |
| SCHEMBL7604320 | 0.72 | LCK (0.35) | ALDH1A1MEN1KMT2AHSD17B10HPGD | |
| SCHEMBL7979012 | 0.69 | KDM4E (0.46) | ALDH1A1MAPTPOLBKDM4E | |
| SCHEMBL627755 | 0.65 | — | — | |
| SCHEMBL12679771 | 0.65 | ALDH1A1 (0.35) | ALDH1A1MEN1ALOX15KMT2AHSD17B10 | |
| SCHEMBL16219593 | 0.62 | RAPGEF4 (0.40) | ALDH1A1MEN1KMT2AHPGDMAPT | |
| SCHEMBL27503899 | 0.62 | — | — | |
| SCHEMBL6589859 | 0.62 | KDM4E (0.41) | ALDH1A1MEN1ALOX15KMT2AHSD17B10 | |
| SCHEMBL12679720 | 0.62 | CYP1A2 (0.38) | ALDH1A1MEN1ALOX15KMT2AHSD17B10 | |
| SCHEMBL12681314 | 0.61 | KDM4E (0.38) | ALDH1A1MEN1ALOX15KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469166-B2 | Thiophenopyrimidines | NEUROCRINE BIOSCIENCES, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020052362-A1 | CRF receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders | WEBB THOMAS R (US) | 2002-05-02 | — | — | US | disclosed |
| EP-0882051-B1 | THIOPHENOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2001-11-07 | — | — | EP | disclosed |
| US-6255310-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | NEUROCRINE BIOSCIENCES INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0882051-A1 | THIOPHENOPYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997029110-A1 | THIOPHENOPYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052362-A1 | CRF receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders | CRHR1, CRHR2, CRH | ALDH1A1 1284/4885MEN1 1940/4885ALOX15 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.